A clinical trial evaluating the safety and efficacy of ABX-EGF [panitumumab] in patients with hormone resistant prostate cancer with elevated PSA [prostate specific antigen] without metastasis
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2010
At a glance
- Drugs Panitumumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 27 Dec 2007 New trial record.